DaBomb Protein Biotech Corp. - Laporan Laba Rugi (TTM)

DaBomb Protein Biotech Corp.
TW ˙ TPEX
NT$ 19.65 ↑0.30 (1.55%)
2024-10-25
BAHAGING PRESYO
Laporan Laba Rugi (TTM)

Laporan Laba Rugi DaBomb Protein Biotech Corp. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 544 605 626 580 531 471 457 465 445 434 418 399 399 384 386 387 357 338 305 298
Change (%) 11.34 3.43 -7.37 -8.36 -11.44 -2.84 1.78 -4.30 -2.65 -3.70 -4.48 -0.01 -3.61 0.48 0.15 -7.78 -5.31 -9.65 -2.34
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 454 506 542 511 488 449 433 449 430 414 395 369 364 338 326 315 284 269 240 236
Change (%) 11.47 7.08 -5.66 -4.44 -8.07 -3.55 3.67 -4.26 -3.61 -4.76 -6.60 -1.29 -7.09 -3.56 -3.29 -9.80 -5.36 -10.90 -1.58
% of Revenue 83.50 83.60 86.55 88.14 91.90 95.40 94.70 96.46 96.50 95.54 94.50 92.40 91.22 87.92 84.38 81.48 79.70 79.66 78.55 79.16
Gross Operating Profit 90 99 84 69 43 22 24 16 16 19 23 30 35 46 60 72 72 69 65 62
Change (%) 10.68 -15.17 -18.33 -37.44 -49.68 11.88 -32.01 -5.26 23.86 18.92 31.93 15.52 32.53 29.94 18.74 1.09 -5.10 -4.74 -5.11
% of Revenue 16.50 16.40 13.45 11.86 8.10 4.60 5.30 3.54 3.50 4.46 5.50 7.60 8.78 12.08 15.62 18.52 20.30 20.34 21.45 20.84
SG&A 62 70 77 80 77 74 72 74 73 70 65 64 66 63 62 61 54 56 51 47
Change (%) 13.03 11.03 3.08 -3.43 -4.50 -2.32 2.69 -0.86 -4.44 -6.40 -3.00 3.48 -4.49 -0.71 -2.59 -11.84 3.89 -8.44 -8.32
% of Revenue 11.35 11.52 12.37 13.76 14.50 15.64 15.72 15.86 16.43 16.13 15.68 15.92 16.48 16.33 16.13 15.69 15.00 16.46 16.68 15.66
R&D 14 14 14 14 13 12 11 12 11 12 12 12 13 14 14 15 15 15 16 16
Change (%) 1.36 0.53 -4.39 -1.08 -12.15 -4.98 7.48 -9.25 8.22 -0.57 1.25 7.11 6.34 4.39 7.62 0.04 -2.15 7.25 -0.41
% of Revenue 2.57 2.34 2.27 2.35 2.53 2.51 2.46 2.59 2.46 2.73 2.82 2.99 3.20 3.54 3.67 3.95 4.28 4.42 5.25 5.36
OpEx 530 590 633 604 579 534 516 535 514 496 472 444 442 414 402 391 353 340 307 299
Change (%) 11.38 7.39 -4.57 -4.23 -7.69 -3.41 3.62 -3.90 -3.48 -4.89 -5.90 -0.38 -6.32 -2.87 -2.80 -9.73 -3.82 -9.70 -2.64
% of Revenue 97.42 97.46 101.19 104.25 108.94 113.55 112.88 114.92 115.39 114.41 113.00 111.31 110.90 107.79 104.19 101.12 98.98 100.54 100.48 100.17
Operating Income 14 15 -7 -25 -48 -64 -59 -69 -69 -62 -54 -45 -43 -30 -16 -4 4 -2 -1 -1
Change (%) 9.62 -148.39 230.92 92.78 34.25 -7.64 17.88 -1.28 -8.86 -13.13 -16.87 -3.65 -31.14 -45.93 -73.18 -183.44 -150.33 -19.36 -64.90
% of Revenue 2.58 2.54 -1.19 -4.25 -8.94 -13.55 -12.88 -14.92 -15.39 -14.41 -13.00 -11.31 -10.90 -7.79 -4.19 -1.12 1.02 -0.54 -0.48 -0.17
Interest Expense -2 -3 -3 -3 -4 -5 -5 -6 -6 -7 -7 -8 -8 -8 -8 -7 -6 -5 -4 -4
Change (%) 21.70 -2.93 1.15 43.83 25.06 19.25 16.38 -1.40 5.03 7.97 9.48 5.60 0.28 -3.97 -9.27 -11.03 -18.41 -13.73 -13.76
% of Revenue -0.39 -0.43 -0.40 -0.44 -0.69 -0.97 -1.19 -1.36 -1.41 -1.52 -1.70 -1.95 -2.06 -2.14 -2.05 -1.85 -1.79 -1.54 -1.47 -1.30
Net Income 3 7 -14 -26 -49 -62 -46 -52 -45 -45 -47 -43 -66 -57 -37 -21 7 12 7 -13
Change (%) 157.54 -296.25 87.57 83.31 28.66 -26.23 13.64 -13.23 -1.68 6.19 -9.45 53.21 -13.33 -35.60 -43.29 -134.67 61.15 -40.79 -290.42
% of Revenue 0.51 1.19 -2.26 -4.57 -9.13 -13.27 -10.07 -11.25 -10.20 -10.30 -11.36 -10.77 -16.50 -14.83 -9.51 -5.38 2.02 3.44 2.26 -4.40

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista